Can Artificial Intelligence Help Diagnose Prostate Cancer?
AI may be a medical game-changer, with the power of machine learning advancing the efficacy of prostate cancer biopsies and m [...]
Andre Esteva of ArteraAI: 5 Things I Wish Someone Told Me Before I Became A CEO
Medium’s Doug Noll spoke with the CEO of ArteraAI, Andre Esteva, to discuss his path from Stanford University to founding fou [...]
ArteraAI and ACS form collaboration to use AI for designing personalized therapy
ArteraAI and the American Cancer Society formed a collaboration focused on the development of AI-driven cancer therapy person [...]
MMAI Model More Accurately Predicts Outcomes of High-Risk Prostate Cancer
Jessica Nye from Cancer Therapy Advisor discusses key findings, presented by Daniel Spratt, MD at ASCO GU 2023, demonstrating [...]
Multimodal AI Biomarker May Help Personalize Decision-Making in High-Risk Prostate Cancer
Mark Leiser from HemOnc Today discusses results from ArteraAI’s prognostic MMAI model that were presented by Daniel Spratt, M [...]
How AI can support the American Cancer Society’s IMPACT Initiative
Andre Esteva, Co-founder and CEO of ArteraAI, discusses how AI can support the ACS’ IMPACT initiative and other possibilities [...]
SUO 2022: External Validation of a Digital Pathology-Based AI Model Predicting Metastasis and Death in High and Very High Risk Men on NRG/RTOG 9902 Phase III Trial
Dr. Ross discusses external validation of an MMAI prognostic model in patients with high- and very high-risk disease. Additio [...]
RSNA 2022: The Development of Pathology-Based Deep Learning Tools to Personalize Treatment Decisions in Radiation Oncology
Dr. Feng discusses the development and validation of pathology-based deep learning predictive and prognostic tools to persona [...]
ASTRO 2022: Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multi-Modal Deep Learning with Digital Histopathology
Dr. Tward discusses how an MMAI prognostic risk stratification model can further risk-stratify within a given NCCN risk group [...]